Enercel News

Enercel Excels

A BRIEF LOOK AT THE PRELIMINARY DATA OBTAINED FROM THE CLINICAL STUDY INVOLVING THE USE OF ENERCEL® IN THE TREATMENT OF PATIENTS WITH CO-INFECTIONS OF HIV AND TB

Background:

Enercel® is a complex homeopathic medication that has been used successfully in the treatment of many infections including drug-sensitive and multi-drug resistant tuberculosis; hepatitis B and C; and diarrhea in children. Tuberculosis and HIV are the #1 and #2 causes of death from infectious diseases in the world. Together as a co-infection, they result in a much more severe and rapidly-progressive illness than either alone. Both of them cause the immune system to work much less efficiently against the other.

Aims:

To evaluate whether Enercel® is efficacious for patients with tuberculosis and HIV co-infection at the Regional Antituberculosis Hospital in Chernigov, Ukraine. Specifically, to improve immune system function [by measuring T-helper or CD4 cells]; lessen or eliminate the amount of HIV virus in the bloodstream [HIV viral load]; and to verify the elimination of tuberculosis in the lungs [sputum AFB smears and cultures].

Methods:

Initially 50 cc Enercel® is given intravenously twice per day for 1 month. This is followed by once daily treatment of 50 cc intravenously for 2 months. Another 7 cc is administered via a nebulizer once daily and 2 puffs are introduced into each nostril three times per day. Additionally 20 drops is given sublingually twice daily. Two control groups consist of giving Enercel® in addition to antiretrovirals [3 or more standard medications given for HIV infection] and the other group received the antiretrovirals alone. All patients receive standard tuberculosis treatment. Patients are evaluated by sputum AFB smears and culture, HIV viral load and CD4 count. Quality-of-Life [QOL] is assessed on a scale of 0 to 100, with 100 being severe incapacitation and 0 being perfect health. Toxicity is monitored by biochemistry panels and complete blood counts.

Results:

After 2 months, there are 7 evaluable patients on Enercel® alone for HIV. Each patient is AFB-smear negative [indicating elimination of tuberculosis in the lungs]. QOL scores improved from a mean of 47.0 at baseline to 20.14 at 2 months [with lower numbers meaning better quality of life].  CD4 counts improved from a baseline mean value of 234.43 to 269.86 cells/mm3 after 2 months [indicating an improved immune system]. Mean viral load counts decreased from a baseline of 556,439 to 58,763 copies/ml at 2 months [meaning almost a 10 fold drop in the amount of HIV particles in the bloodstream]. There was no toxicity attributed to Enercel®. Two patients in each of the two control groups have their results pending.

Enerpuncture:

 

Acupuncture injection point therapy using Enercel® [Enerpuncture] was used in 2 patients: 1) Patient had a right-sided stroke from TB meningitis. She was treated with 2 months of Enerpuncture on her right upper and lower extremities. She is now able to move her right shoulder and arm and she can walk with a slight limp 2) Patient had HIV/TB nerve damage of his lower extremities to the point that he could not stand without support. He is now able to walk on his own with a cane.

Conclusions:

Enercel® is a safe, low-cost, homeopathic medication that has shown preliminary efficacy in the management of HIV infection associated with tuberculosis.  Immune system function was improved, HIV in the bloodstream was markedly reduced and tuberculosis was eliminated in the lungs. These results are particularly noteworthy for the following two reasons:  1) Co-infection with TB and HIV is much more difficult to treat than either infection alone and 2) This is the first study to show that a single medication [Enercel®] is able to effectively treat both a severe viral [HIV] and bacterial [TB] infection simultaneously. The study is ongoing with newly enrolled patients into the study and 3 month results of the initial patients available in about 6 weeks.

Promise for the future

Promise for the future in yesterday’s Remedies: traditional therapies to modern medicine.

Dr Sukhatme gave this lecture at the National Institutes of Health’s Stephen E Straus Distinguished Lecture on December 15, 2010 entitled:

Promise for the future in yesterday’s Remedies: traditional therapies to modern medicine. 

(Notice the distinction he makes between what is considered traditional medicine today i.e., allopathic or main stream medicine vs. actual traditional medicine which is actually medical therapies before modern medicine that have merit.)

Vikas P. Sukhatme MD  PhD is a physician-scientist working in cancer research. He first trained as a theoretical physicist but then switched careers.  He went to medical school and then trained in medical research and is currently the Chief Academic Officer at Beth Israel Deaconess Medical Centre, (BIDMC) a teaching hospital of Harvard Medical School.   BIDMC is one of the leading academic medical centres in the US, dedicated to clinical care, education and research.

Dr Sukhatme is also the co-founder of GlobalCures , a non-profit medical research organization with a mission to help patients find their best treatment options today, share their clinical outcomes and fund promising therapies.  http://www.global-cures.org

Dr David Christner Gusi Peace Prize

Tropical Diarrhea

Newspaper Article Announcing

Results of Study (in Spanish)

Diarrhea Newspaper writeup

Gusi Peace Prize

David Christner

The 2012 Gusi Peace Prize has been awarded to Dr David Christner from the USA.  Dr Christner is the CEO of World Health Advanced Technologies, Ltd and founder of the self-funded Cambridge Christner Foundation which has been instrumental in building five schools and four orphanages in Cambodia, and a large 42-room school in North Korea as well as spear heading important research and clinical trials involving patients with tuberculosis and Human Immunodeficiency Virus using a complex homeopathic Enercel®.

Also honored this year was Dr. Valery Pavlovich Dubrov of Ukraine.  He is Chief of the Regional Antituberculosis Hospital in Chernigov, who significantly advanced the state-of-the-art tuberculosis treatment in Eastern Europe, developing new modalities for the early diagnosis of tuberculosis; he also established the differential diagnosis of pulmonary disease in Ukraine.  He promoted the Direct Observed Treatment of TB, which became the national standard, both for inpatient as well as ambulatory patients and is heading up the clinical trial with Dr Dariel Laurent at the Antituberculosis Hospital using Enercel®.

Dr. Christner shares an honor bestowed on many distinguished individuals such as; Hollywood actor Anthony Quinn, President Fidel V. Ramos of the Philippines, Behgjet Pacolli, Former President of Kosovo and First Deputy Prime Minister of Kosovo.  This is just a sample of many laureates honored over the years by the Gusi Peace Prize Foundation.

Barry Gusi and Daniel Amar Siad created the Gusi Peace Prize Foundation which performs humanitarian work for poor communities in the Philippines.  It is based in Manila and awards the Gusi Peace Prize to distinguished individuals working toward the attainment of peace and respect for human life and dignity.  This prestigious award recognizes 10 – 15 persons, throughout the world, each year that have made exemplary contributions to peace and human rights, the sciences or the arts.   

On March 17, 2008, President Gloria Macapagal-Arroyo signed Presidential Proclamation No. 1476, declaring every fourth Wednesday of November as the “GUSI PEACE PRIZE INTERNATIONAL FRIENDSHIP DAY”.

The Gusi Peace Prize has become one of the foremost peace prizes in Asia and the whole world; it approximates the honor and respect accorded to the Nobel Peace Prize of Norway, and the Pulitzer of the United States of America.

Press Release HIV and TB Study

New hope for patients with concurrent TB and HIV infection.

 

Early results “Spectacular!” according to researchers using Enercel® to treat patients with Tuberculosis and HIV in an ongoing clinical trial at the Antituberculosis Hospital in Ukraine.

 

December 21, 2012 may not be the end of the world but just might be the “end” for those suffering from concurrent infections of the tuberculosis bacterium (TB) and the human immunodeficiency virus (HIV) and the beginning of hope for a new life.

According to estimates by the World Health Organization there are 11.4 million people infected with both tuberculosis (TB) and human immunodeficiency virus (HIV).  The primary cause of death of those dually infected is from TB not HIV.  Health officials estimate that 2 out of 10 people in the USA who are infected with TB are also infected with HIV. 

With nearly one third of the world’s population infected with Tuberculosis the very positive results coming out of the Ukraine marks perhaps one of the most important milestones for world health and the impact of Enercel® on making this world a better place for all mankind.

As we approach the completion of this clinical study we will be announcing the final results on our website http://www.enercel.com and the news channels of the world, so stay tuned.

Enercel® is scientifically and clinically proven to be 100% non-toxic and effective as a complex homeopathic formulation.  Visit their website at http://www.enercel.com to review the many studies that have been performed over the last 21 years.

W.H.A.T.’s mission is to make this valuable product available worldwide to all that desire a safe and effective solution to chronic illness and a pathway to a healthy life, today we are a giant step closer to our goal.

News about TB

Enercel® Tuberculosis Study, Chernigov, Ukraine completed February 2012

Tuberculosis! A disease thought by Western Minds to have been eradicate decades ago.  According to recent internet research that is not the case.

It was found that one third of the world’s population is thought to be infected with “Mycobacterium tuberculosis” a strain of bacteria that causes TB and new infections are occurring at a rate of one per second.  Like a tsunami, it is once again spreading across the developing world and with modern day travel removing the natural barriers that prevent worldwide spreading of a disease; all continents need to watch for signs of tuberculosis.

Researchers at W.H.A.T were appalled when they became aware of this resurgence of TB.  Knowing that Enercel® had the potential to be of great use in treating TB they began planning a clinical trial.  The proper people were quickly contacted and as soon as regulators approved, W.H.A.T. delivered all the Enercel® needed for the study to the Hospital at no cost to the hospital.  It was the foresight of Valerij Dubrov, MD of the Regional Antituberculosis Hospital in Chernigov, Ukraine, that started the process.  He acted as investigator along with Valentina Suhareva, MD and Tatiana Dubrov, MD.  Fifteen patients were involved; some were fighting TB-MDR, (multiple drug resistant tuberculosis) as well as TB-S (drug sensitive tuberculosis).  W.H.A.T. team members, Drs. David Christner and Dariel Laurent prepared the protocols and monitored the 30 day study.

The results, after only 30 days, were monumental.  Six of the seven TB-S patients were considered 100% Tuberculosis free.  The seventh patient required an additional 10 days of treatment with Enercel® to be 100% TB free.  Within those 30 days three of the eight TB-MDR patients became TB free.  Two other patients joined this state after another 6 weeks of treatment with Enercel® and the remaining three TB-MDR patients had significantly improved quality of life scores (QOL) which for them translated into decreased coughing, improved appetite and the ability to gain weight, an exciting new perspective for these patients.

Admittedly, this was a very short study.  To have this much success in such a short time span was truly remarkable.  The normal outcome with standard treatment takes a minimum of 6 months of treatment for those who survive.  According to World Health Organization (WHO) estimates, each year, 8 million people worldwide develop active tuberculosis and nearly 2 million die.  This clinical study by W.H.A.T. is highly suggestive that Enercel® may help reduce that mortality figure in a very positive way.   The scientific community needs to further advance studies using Enercel®.

More studies are currently being planned and a study is underway presently in the Ukraine involving patients with tuberculosis and HIV concurrently.  Never before has one product been used to treat both a viral and a bacterial disease at the same time.

Other studies of Enercel®’s effect on Chronic diseases are planned for the near future including multiple breast cancer studies in Asia, Hepatitis B studies in Thailand, Neuroblastoma in children will be studied in Switzerland and a Lung Cancer study in the Ukraine.

Enercel® is scientifically and clinically proven to be 100% non-toxic and effective as a complex homeopathic formulation.  Visit their website at http://www.enercel.com to review the many studies that have been performed over the last 21 years.

W.H.A.T.’s mission is to make this valuable product available worldwide to all that desire a safe and effective solution to chronic illness and a pathway to a healthy life.

© 2018 Enercel | Nature Advanced - Disclaimer | Privacy Policy | Terms of Service
Top